Let’s take a look at the treatments offered by three, up and coming, BioTech companies with cutting edge therapies, that are currently on our watch list!
(No positions at this writing):
Syndax Pharmaceuticals:
- Axatilimab: An anti-CSF-1R monoclonal antibody. It’s being developed for chronic graft-versus-host disease (cGVHD) and other immune-mediated diseases where CSF-1R-dependent monocytes and macrophages contribute to organ fibrosis.
- Revumenib: Received FDA Breakthrough Therapy Designation for treating adult and pediatric patients with relapsed or refractory KMT2A-rearranged MLLr acute leukemia.
Autolus Therapeutics:
- Autolus is focused on developing next-generation programmed T-cell therapies for cancer. They have several clinical-stage candidates, including AUTO1, AUTO3, and AUTO4, which target different types of leukemia and lymphoma. These therapies are still in clinical trials.
Xencor Inc.:
- Xencor is known for its XmAb antibody engineering platform. While they don’t have direct treatments, they collaborate with other companies to develop novel therapies using their technology
- -----------------------------------------------------------------------------------------------------------------------------------------
In summary, Syndax Pharmaceuticals has made notable progress, while Autolus Therapeutics is primarily in clinical trials, and Xencor focuses on antibody engineering.
As of today, Autolus Therapeutics and Syndax Pharmaceuticals have been in the spotlight, with analysts weighing in on their potential. Let’s take a closer look:
Autolus Therapeutics (AUTL):
- Needham analyst Gil Blum maintains a Buy rating on Autolus Therapeutics, setting a price target of $9.00. The company’s shares closed last Friday at $4.501.
- Autolus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies.
- They recently announced the acceptance of a Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel), which targets patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (B-ALL)2.
Syndax Pharmaceuticals (SNDX):
- Syndax is advancing the next generation of targeted treatments for cancer. They focus on acute leukemias and chronic graft-versus-host disease.
- Recently, Syndax reported its financial results for the first quarter of 2024 and provided a business update
- There’s no specific information regarding any of the three being takeover targets at the moment.
- Keep an eye on news and analyst reports for any updates on these companies and remember, that, the big dogs of BioTech are always on the lookout for smaller companies with great new technology!
